Press release
Depression Drugs Market Size, Share, Trends Analysis & Competition through 2026 | Key Players are Novartis AG, Allergan USA Inc., AstraZeneca, etc.
Request Market Report Sample - https://www.factmr.com/connectus/sample?flag=S&rep_id=3215
Depression comprises multiple mental health challenges characterized by the absence of positivity, which leads to feelings such as misery, sadness, and anxiety. Such feelings are normal only if they exist for a short period of time and it becomes a serious condition when the individual feels lost, angry, frustrated, and gloomy very frequently. Although prevalence of depression has gone up in the last decade, demand for depression drugs has witnessed a decline, as other forms of therapies, notably cognitive behavior therapy (CBT) has gained popularity. According to a study by the National Institute of Mental Health, over 10 Mn adults in the U.S. suffered from at least one depressive episode with severe results in 2016. The same study captured that the prevalence of depression is higher among female adults with 8.5% of cases as compared to 4.8% male adults. Increase in the geriatric population and chronic diseases have been the crucial drivers for the growth of depression drugs market. With the rise in the health consciousness among the consumers, side-effects of the depression drugs are recognized and advanced technologies for the development of drugs with lesser side-effects are being used. However, the inclination of the consumers towards non-pharmacological therapies like CBT and meditation is likely to beset the growth of the global depression drugs market.
US Continues to Push Demand for Depression Drugs
North America constitutes the largest share of the global depression drugs market, given the high concentration of established market players, which are focusing on enhancing the efficiency of these drugs. In addition, a rise in the awareness pertaining to the depression disorders created by mental healthcare organizations is expected to drive the growth of the market in this region. However, with increasing awareness pertaining to the health threats posed by the side-effects of the depression drugs, the consumers are gradually favoring non-clinical treatments over these drugs, which is anticipated to challenge the growth of the global market. Following the trends of North America, Europe accounts for the second largest share of the depression drugs market, which can be attributed to the proliferated research and development activities to rethink the efficiency of depression drugs in this region.
According to the study, depression drugs lose their efficacy after a few months or years since the brain becomes less responsive to such drugs. As a result, the normal brain functions begin to hamper. Symptoms such as blurred vision, vivid dreams, insomnia, fatigue, dizziness, and loss of coordination are observed by the patients who discontinue the intake of the drugs. These after-effects caused by these drugs are anticipated to limit the growth of the global depression drugs market.
Global Depression Drugs Market – Competitive Matrix
According to the report, the significant players operating in the depression drugs market comprise of Johnson and Johnson, Sebela Pharmaceutical Inc., Takeda Pharmaceutical Company Ltd., GlaxoSmithKline, Novartis AG, Allergan USA Inc., AstraZeneca, Pfizer Inc., Eli Lilly and Company, Otsuka Pharmaceutical Co., Ltd., Alkermes Plc, Bristol Myers Squibb Co., H. Lundbeck, and Teva Pharmaceutical Industries Ltd., among others.
Ask Industry Experts about this Report - https://www.factmr.com/connectus/sample?flag=AE&rep_id=3215
These leading players of the depression drugs market are adopting sustainable growth strategies to diversify their product portfolio, sustain their position in the global market, intensify their customer base, and garner share in the global depression drugs market.
Contact Us
FactMR
11140 Rockville Pike
Suite 400, Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Read Industry News at: https://insiderstribune.com
About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Depression Drugs Market Size, Share, Trends Analysis & Competition through 2026 | Key Players are Novartis AG, Allergan USA Inc., AstraZeneca, etc. here
News-ID: 1828401 • Views: …
More Releases from Fact.MR
Carbon Felt and Graphite Felt Market: Forecasted Valuation of US$ 1.07 Billion b …
According to Fact.MR, a source of competitive intelligence and market research, the global Carbon Felt And Graphite Felt Market (カーボンフェルトおよびグラファイトフェルト市場) is expected to grow at a remarkable rate of growth of 9.6%, with a valuation of US$ 1.07 billion by the end of 2032. The market saw a compound annual growth rate (CAGR) of 7.6% from 2017 to 2021. The market is expanding due to factors such as the increased…
Land Survey Equipment System Market Eyes US$ 12.21 Billion Milestone by 2032
According to Fact.MR, a company that offers competitive intelligence and market research, the global Land Survey Equipment Systems Market (土地測量機器システム市場) is expected to be worth US$ 7.79 billion in 2022 and grow at a compound annual growth rate of 4.6% from 2022 to 2032. Fact.MR predicts that the market for enhanced land survey equipment systems will grow in the coming years due to the pressing necessity to use terrestrial scanners.…
E-Beam Wafer Inspection System Market: Forecasted Surge to US$ 3.5 Billion by 20 …
According to a new industry report by market research and competitive intelligence source Fact.MR, the global E-Beam Wafer Inspection System Market (電子ビームウェーハ検査システム市場) is expected to reach US$ 3.5 billion by 2033, growing quickly at an 18.3% CAGR from 2023 to 2033. An e-beam wafer inspection system is a semiconductor fabrication tool that inspects wafers, or integrated circuit (IC) components, using electron beam scanning. It is used to find flaws in…
Automotive Engine Cover Market: Driving Toward a $1.8 Billion Revenue Milestone …
Fact.MR: A Supplier of Competitive Intelligence and Market Research: The demand for Automotive Engine Cover (自動車エンジンカバー市場) is expected to generate US$ 1.8 billion in sales by the end of 2033, with a market estimate of US$ 1.3 billion in 2023. Over the next 10 years, the global market for automobile engine covers is expected to grow at a compound annual growth rate of 3.3%. Engine covers for cars are mostly…
More Releases for Depression
Increase in the prevalence of anxiety disorders and depression is bolstering the …
The research report "Global Anxiety Disorders and Depression Treatment Market: By Product Type (MAOIs (Monoamine Oxidase inhibitors), Atypical Antipsychotics, Benzodiazepines, Anticonvulsants, Beta-Blockers, SRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TeCAs (Tetracyclic Antidepressants), TCAs (Tricyclic Antidepressants), Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Others), and Geography- Global/Region/Country Forecast to 2028." The global anxiety disorders and depression treatment market size was valued at USD 8.2 Bn in the year…
Depression Treatment Device Market: Information by Product Type (Light Therapies …
Depression is characterized by multiple mental health challenges that involve a lack of positivity, suicidal thoughts, insomnia, anxiety, loss of appetite, and sadness. Depression is caused by a combination of biological, genetic, environmental, and psychological factors. Globally, the prevalence of depression is increasing at an alarming rate. About 300 million people of all ages suffered from depression and the suicide rate rose to about 8,00,000 individuals in 2018. As per…
Depression Cannot Hit A Moving Target
Cottonwood Heights, Utah, Mar 12, 2020 -- Depression can't hit a moving target. That was a phrase to live by for Chelsea Hansen. She was full of life and love, and she had big goals. But soon she was to discover that life doesn't turn out the way she planned.
Behind the Fake Smile is a fictional book based on real-life experiences. It's the story of how Chelsea navigates a world…
Depression Drugs Market: Increase in Cases of Depression to Boost Market Growth
Transparency Market Research (TMR) has published a new report titled, “Depression Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global depression drugs market was valued at US$ 6,500 Mn in 2017 and is anticipated to decline at a CAGR of 2% from 2018 to 2026. The report suggests that rise in incidence of major depression disorders is projected to drive…
Depression Therapeutics Market Forecast till 2025
Antidepressants are used to treat a wide range of mental disorders, including depression, anxiety, and major depressive disorder. Certain neurotransmitters in the brain exist in chemical form such as dopamine and serotonin, which are responsible for maintaining emotional balance such as mood and behavior. Antidepressants cover a wide range of drug categories, including selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants…
Depression Drug Market: Global Depression Drug Forecast Will Reach $16.8 billion …
Zion Market Research has published a new report titled “Depression Drug (Benzodiazepines, SNRIs, TCAs, TeCAs, Atypical Antipsychotics, Monoamine Oxidase inhibitors and Others) Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2014 – 2020” According to the report, the global depression drug market was valued at USD 14.51 billion in 2014 and is expected to generate revenue of USD 16.8 billion by end of 2020, growing at a CAGR of 2.50%…
